Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
5.78
+0.23 (4.14%)
At close: Jan 17, 2025, 4:00 PM
5.80
+0.02 (0.33%)
After-hours: Jan 17, 2025, 6:10 PM EST
Acrivon Therapeutics Employees
As of December 31, 2023, Acrivon Therapeutics had 61 total employees, including 58 full-time and 3 part-time employees. The number of employees increased by 17 or 38.64% compared to the previous year.
Employees
61
Change (1Y)
17
Growth (1Y)
38.64%
Revenue / Employee
n/a
Profits / Employee
-$1,261,918
Market Cap
179.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ACRV News
- 5 weeks ago - Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
- 3 months ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewsWire
- 4 months ago - Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects - Seeking Alpha
- 4 months ago - Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis - GlobeNewsWire
- 7 months ago - Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias? - Seeking Alpha
- 8 months ago - Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 8 months ago - Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire